Currently, as the concept and strategy of cancer theranostics further evolves into clinical management of cancer patients, we believe the future development of PSMA-targeting agents is for personalized precision treatment enabled by quantitative imaging using either radiotheranostic or chemotheranostic agents. This evidence concerns the gene FOLH1 and cancer.